Montefiori DC, Karnasuta C, Huang Y, et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials[J]. J Infect Dis. 2012; 206(3): 431-41.
[2]
Doria-Rose NA, Klein RM, Daniels MG, et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables[J]. J.Virol. 2010, 84(3):1631-6.
[3]
Mascola JR, Souza PD, Montefiori DC, et al. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodefiency virus type 1 vaccines[J]. J. Virol. 2005, 79:10103-10107.
[4]
Nie J, Wang W, Wen Z, et al. Optimization and proficiency testing of a pseudovirus-based assay for detection of HIV-1 neutralizing antibody in China[J]. J.Virol.Methods. 2012, 185(2):267-75.
[5]
Hu XT, Hong KX, Zhao CH, et al. Neutralization pattern of HIV-1 subtype B’ and CRF07_BC virus chronically infected individuals[J]. China Trop Med.2011,11(4):391-394.(In Chinese)
Todd CA, Greene KM, Yu X, et al. Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells[J]. J. Immunol. Methods. 2012, 375(1-2):57-67.
[8]
Wang YC, Nie JH, Wu XL, et al. Establishment and application of pseudovirus detection platform[J]. Chin J MicrobiolImmunol, 2013,33(1): 40-46. (In Chinese)
Buchbinder A. The envelope of HIV-1 as a key component to infectivity[J]. Prog. AIDS Pathol. 1990, 2: 1-11.
[11]
Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies[J]. Nat. Rev. Immunol. 2004, 4(3):199-210.
[12]
Hu XT, Hong KX, Shao YM. Advance in identification and analysis of epitope specificities of broadly neutralizing anti-HIV-1 sera[J]. China TYrop Med.2011,11(5): 636-639.(In Chinese)
Kwong PD, Mascola JR.Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies[J]. Immunity. 2012, 37(3):412-25.
[15]
Polonis VR, Brown BK, Rosa Borges A, et al. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination[J]. Virol. 2008, 375(2): 315-20.
